{"id":"W2890261294","doi":"10.1093/annonc/mdz135","title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":840,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research; Merck","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Oncology; Internal medicine; Cancer; Phases of clinical research; Gynecology; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03553001180780957,"score_gpt":0.3693015059763449,"score_spread":0.3337714941685354,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}